Abstract
The c-myc gene product is known to be involved in the regulation of cell proliferation and differentiation. Altered c-myc gene expression is a common event in a variety of tumors. This study was designed to investigate c-myc overexpression in transitional cell carcinoma (TCC). The first part was designed to investigate the frequency of c-myc overexpression in relation to tumor stage and tumor grade. A second set of experiments was directed at the mechanisms underlying c-myc overexpression in TCC. A total of 185 paraffin-embedded urothelial tissue specimens were investigated immunohistochemically for c-myc overexpression. A single case of overexpression (6%) was observed in normal urothelial tissue (n=16). c-myc overexpression was also infrequent in carcinoma in situ (TIS) (7/39=18%). In contrast, papillary urothelial tumors (n=65) yielded c-myc overexpression in 38 cases (58%). Investigation of infiltrating bladder tumors revealed c-myc overexpression in 56% of T1 tumors and 59% of muscle-infiltrating tumors. The staining pattern in multifocal tumors was heterogeneous in 10 of 18 cases. Similarly, only 12 of 28 patients with tumor recurrences showed the same c-myc staining pattern in the primary tumorand in tumor recurrences. c-myc overexpression did not correlate with tumor grade or tumor progression. Nevertheless, the high frequency of c-myc overexpression in urothelial carcinoma suggests an important role for this protein in urothelial carcinoma. Therefore, the mechanism underlying c-myc overexpression was further investigated in six bladder carcinoma cell lines. Southern blot experiments under standardized conditions showed no significant gene amplification. The comparison of c-myc mRNA expression to that of histoneH3 as a measure of cell proliferation revealed a moderate correlation (r=0.45) in the six cell lines examined. These data suggest that in accord with its established role as a cell cycle competence factor, c-myc may be necessary but not sufficient for the induction of proliferation in urothelial carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altmann DG (1991) Statistics for medical research. Chapman and Hall, London
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156
Cox DR (1972) Regression models and life tables (with discussion). R Roy Stat Soc B 34:187
Del Senno L, Maestri I, Piva R, Hanau S, Reggiani A, Romano A, Russo G (1989) Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol 142:146
DePinho RA, Schreiber-Agus N, Alt FW (1991)Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57:1
Evan GI, Littlewood TD (1993) The role of c-myc in cell growth. Curt Opin Genet Devel 3:44
Galaktionov K, Chen X, Beach D (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382:511
Grimm MO, Jürgens B, Schulz WA, Decken K, Makri D, Schmitz-Dräger BJ (1995) Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res 23:293
Hasse A, Schulz WA (1994) Enhancement of reporter gene de novo methylation by DNA fragments from theα-fetoprotein control region. J Biol Chem 269:1821
Hermanek P, Sobin LH (1992) TNM classification of malignant tumours. 4th edn. Springer-Verlag, Berlin Heidelberg New York
Koss LG (1975) Tumors of the urinary bladder. In: Firminper HI (ed) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC, pp 62
Lipponen PK (1995) Expression of the c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 175:203
Marcu KB, Bossone SA, Patel AJ (1992)Myc function and regulation. Annu Rev Biochem 61:809
Masters JRW, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, Franks LM (1986) Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 46:3630
Masters JRW, Vesey SG, Munn CF, Evan GI, Watson JV (1988) C-myc oncoprotein levels in bladder cancer. Urol Res 16:341
Mostofi FK (1973) Histological typing of urinary bladder tumours. Offset Publication 10. WHO, Geneva
Murphy WM, Soloway MS (1982) Urothelial dysplasia. J Urol 127:849
Oeto R, Pyke MC, Armatage NE (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 35:53
Sauter G, Carroll P, Moch H, Kallioniemi A, Kerschmann R, Narayan P, Mihatsch MJ, Waldman FM (1995) C-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 146:1131
Sikora K, Chan S, Evan G, Gabra H, Markham N, Steward J, Watson J (1987) C-myc oncogene expression in colorectal cancer. Cancer 59:1289
Spencer CA, Groudine M (1991) Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56:1
Steward J, Evan G, Watson J, Sikora K (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1
Tashiro H, Miyazaki K, Okamura H, Ivai A, Fukumoto M (1992) C-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 50:828
Teubner B, Schulz WA (1995) Regulation of DNA methyltransferase during differentiation of F9 mouse embryonal carcinoma cells. J Cell Physiol 165:284
Williams RD (1980) Human urologic cancer cell lines. Invest Urol 17:359
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmitz-Dräger, B.J., Schulz, W.A., Jürgens, B. et al. c-myc in bladder cancer Clinical findings and analysis of mechanism. Urol. Res. 25 (Suppl 1), S45–S49 (1997). https://doi.org/10.1007/BF00942047
Issue Date:
DOI: https://doi.org/10.1007/BF00942047